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Dear Editor, 
 
We read with interest the updated AGNP Consensus Guidelines for Therapeutic Drug 
Monitoring (TDM) in Neuropsychopharmacology recently published in the journal. [1]. In this new 
version, the Authors have updated the available knowledge on the pharmacokinetics and 
pharmacogenetics of drugs used in psychiatry and neurology. In particular, the therapeutic reference 
ranges of 18 drugs have been revised, and novel reference ranges have been newly introduced for 28 
drugs on the basis of recent published literature. In addition, the drug concentration-to-dose ratios have 
been extended to 120 neuropsychiatric drugs and introduced for 26 metabolites. Taken together, these 
updates have greatly improved the knowledge of the pharmacology of central nervous system, 
emphasizing at the same time the key role of TDM as a tool to individualize drug doses in psychiatric 
patients in the era of “precision medicine”.  
We believe, however, that the updated guidelines have missed the important opportunity to face with, 
and to provide useful information on, the emerging issue of long-acting injectable (LAI) formulations 
of atypical antipsychotics. The role of LAI formulations - which have been developed as alternative to 
oral regimens, to sustain the release of the drug over a period of weeks, increasing the dosing interval 
time and improving patient adherence – is indeed growing [2-5].   
Currently available LAI of second generation antipsychotics include aripiprazole, olanzapine, 
paliperidone and risperidone. According to the 2017 AGNP-TDM consensus guidelines, the level of 
recommendation for measuring concentrations in blood of these drugs is scored as “1” (strongly 
recommended) or “2” (recommended). Therapeutic ranges have been proposed for each of these drugs, 
but it should be emphasized that these ranges are derived from studies dealing exclusively with drugs 
given as oral formulation. Therefore, their applicability in patients treated with the LAI formulations 
have not been established yet.  
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This limitation opens the unaddressed question on how (and if) TDM should be applied also in patients 
shifted to or on maintenance therapy with LAI formulations of antipsychotics, as well exemplified 
below by our real life data.  
In 2012 we have set up a TDM laboratory service for the assessment of plasma trough concentrations 
of antipsychotics by validated LC-MS/MS methods [6-7]. Looking in our database, we identified 81 
patients on LAI antipsychotics (22 on aripiprazole, 28 on olanzapine and 31 on paliperidone) with 
multiple assessments (usually every two or four weeks). Interestingly, a high percentage of the samples 
resulted below the minimum effective antipsychotic concentrations suggested by the AGNP Guidelines 
whereas only a small percentage of the samples exceeding the upper threshold of the therapeutic ranges 
(Table 1). Despite the observation that patients on LAI just before the next injection show 
concentrations that were under the therapeutic range proposed for oral formulation, they were in any 
case clinically stable according to the physician who evaluated treatment efficacy by reduction of Brief 
Psychiatric Rating Scale (BPRS) and Positive and Negative Symptom Scale (PANSS). 
These findings might raise the hypothesis that, also in the presence of the same drug, specific 
therapeutic reference ranges according to pharmaceutical formulations should be defined, especially for 
LAI, which present peculiar pharmacokinetic characteristics. We are of course aware that TDM data 
regarding these formulations are limited and that until new data are available, for instance regarding 
risperidone, the same therapeutic reference range has been proposed even if as underlined by the 
authors this may result in a gross simplification [8]. We are confident that, such data would increase in 
the near future allowing the inclusion of new tables dealing with LAI antipsychotics in the next AGNP 
guidelines.   
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Table 1:  Distribution of long acting injectable antipsychotic drug trough concentrations 
according to reference ranges of the updated AGNP guidelines 
 
Drug Reference range  
 (ng/mL) 
Samples  
(n) 
Sub-therapeutic  
samples, n (%) 
Supra-therapeutic  
Samples, n (%) 
Aripiprazole 100-350 129 47 (36.4%) 5 (3.8%) 
Olanzapine 20-80 352 206 (58.5%) 3 (0.9%) 
Paliperidone 20-60 430 138 (34.2%) 13 (3%) 
 
